Anika Therapeutics, Inc.
ANIK
$14.88
-$0.14-0.93%
NASDAQ
| 03/31/2026 | 12/31/2025 | 09/30/2025 | 06/30/2025 | 03/31/2025 | |
|---|---|---|---|---|---|
| Net Income | -3.76% | 101.34% | -- | -4,411.36% | -7.95% |
| Total Depreciation and Amortization | -11.62% | -8.09% | -- | -38.44% | -22.83% |
| Total Amortization of Deferred Charges | -- | -- | -- | -- | -- |
| Total Other Non-Cash Items | 133.63% | -82.94% | -- | 26.86% | -47.42% |
| Change in Net Operating Assets | -3,315.24% | 52.14% | -- | 52.34% | 93.56% |
| Cash from Operations | -3,627.69% | 193.11% | 36.96% | 82.32% | -3.17% |
| Capital Expenditure | 49.33% | 50.42% | -- | 56.89% | -56.19% |
| Sale of Property, Plant, and Equipment | -- | -- | -- | -- | -- |
| Cash Acquisitions | -- | -- | -- | -- | -- |
| Divestitures | -- | -- | -- | -- | -- |
| Other Investing Activities | -- | -- | -- | -- | -- |
| Cash from Investing | -174.10% | 115.15% | 4.63% | 84.16% | 192.48% |
| Total Debt Issued | -- | -- | -- | -- | -- |
| Total Debt Repaid | -- | -- | -- | -- | -- |
| Issuance of Common Stock | -- | -19.53% | -- | -43.75% | -- |
| Repurchase of Common Stock | -90.27% | 2.35% | -- | 94.79% | -136.85% |
| Issuance of Preferred Stock | -- | -- | -- | -- | -- |
| Repurchase of Preferred Stock | -- | -- | -- | -- | -- |
| Total Dividends Paid | -- | -- | -- | -- | -- |
| Other Financing Activities | -- | -- | -- | -- | -- |
| Cash from Financing | -90.27% | 1.40% | 99.67% | 116.11% | -139.24% |
| Foreign Exchange rate Adjustments | -126.85% | 50.00% | -- | 254.02% | 448.39% |
| Miscellaneous Cash Flow Adjustments | -- | -- | -- | -- | -- |
| Net Change in Cash | -334.56% | 90.23% | 1,162.33% | 96.49% | 10.62% |